Background. Breast cancer subtypes (BCS) determined from immunohistochemical staining have been correlated with molecular subtypes and associated with prognosis and outcomes, but there are limited data correlating these BCS and axillary node involvement. This study was conducted to assess whether BCS predicted for nodal metastasis or was associated with other clinicopathologic features at presentation. Methods. Patients with stage I/II disease who underwent breast-conserving surgery and axillary surgical assessment with available tissue blocks underwent a institutional pathological review and construction of a tissue microarray. The slides were stained for estrogen receptor, progesterone receptor, and HER-2/neu (HER-2) for classification into BCS. Nodal involvement and other clinicopathologic features were analyzed to assess associations between BCS and patient and tumor characteristics. Outcomes were calculated a function of BCS. Results. The study cohort consisted of 453 patients (luminal A 48.6 %, luminal B 16.1 %, HER-2 11.0 %, triple negative 24.2 %), of which 22 % (n = 113) were node positive. There were no significant associations with BCS and pN stage, node positivity, or absolute number of nodes involved (p [ 0.05 for all). However, there were significant associations with subtype and age at presentation (p \ 0.001), method of detection (p = 0.049), tumor histology (p \ 0.001), race (p = 0.041), and tumor size (pT stage, p \ 0.001) by univariate and multivariate analysis. As expected, 10-year outcomes differed by BCS, with triple negative and HER-2 subtypes having the worse overall (p = 0.03), disease-free (p = 0.03), and distant metastasis-free survival (p \ 0.01).
Prognostic variables for early-stage breast cancer have traditionally included number of lymph nodes involved, tumor size and extent of disease (e.g., metastasis), which subsequently has been incorporated into tumor, node, metastasis classification system staging. 1 More recently, both morphological and immunohistochemical analyses analysis have been incorporated to determine prognosis. 2, 3 Molecular subtypes are predictive of responses to specific therapies and are prognostic for clinical outcomes. 2, 4, 5 Specifically, molecular gene expression for estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu (HER-2) allows a higher order of classification that has been correlated to outcomes. 6, 7 Subsequently, the use of immunohistochemical analysis as a surrogate for molecular profiling has been verified to estimate the prevalence of these molecular subtypes, allowing for more widespread utilization of this higher order of tumor distinction in the clinical setting to provide important insight into management strategies and risk of distant metastasis. [8] [9] [10] [11] An additional advancement in breast cancer management has been identification of patients who are candidates for a more minimalistic approach to the axilla. In essence, sentinel lymph node biopsy has become the standard of care for the management of breast cancer, primarily because of its accuracy in identifying the sentinel node and node negative patients, thus allowing for omission of a full axillary dissection in selected patients. 4, 5, 12 Although both tumor breast cancer subtype (BCS) and pN stage are both independently demonstrated as prognostic, there is a paucity of data describing the relationship between these two factors. [13] [14] [15] [16] Consequently, the primary objective of this investigation was to determine whether BCS correlates to axillary node involvement in early-stage breast cancer. The secondary objectives were to investigate whether there is an association between BCS and other clinicopathologic parameters at presentation, and finally to conduct a confirmatory analysis of the relationship between BCS and outcomes.
MATERIALS AND METHODS

Patient Population
The inclusion criteria for this study included: (1) stage I/ II breast-conservation therapy patients, (2) availability of paraffin-embedded tissue blocks of the primary tumor, and (3) complete clinical records. All patients underwent breast conserving surgery and surgical assessment of the axilla at our institution. Systemic therapy was delivered at the discretion of the treating medical oncologist. Neoadjuvant chemotherapy patients were excluded. The radiation therapy consisted of conventionally fractionated, whole-breast radiation delivered using 2D/3D standard tangential techniques with regional nodal radiation, if indicated, with a boost delivered to the lumpectomy cavity in the vast majority of patients as previously described. 10, [17] [18] [19] The median tumor dose for the cohort was 64 Gy.
Before the pathologic/molecular analysis, departmental chart reviews were conducted on the study cohort to obtain updated follow-up parameters (changes in patient demographics and outcomes such as local, regional, distant relapse, and survival events). These were cross-referenced with our institutional Tumor Registry for accuracy. Institutional review board approval was obtained through our institution's human investigations committee.
Immunohistochemical Analysis
A tissue microarray was constructed by our institution's department of pathology to determine BCS of eligible patients. The hematoxylin and eosin-stained slides of archived formaldehyde-fixed, paraffin embedded blocks of the primary tumor were used to develop representative tumor sections and assembled into a tissue microarray with twofold redundancy for immunohistochemical analysis, as previously described. 20 Antibodies included: mouse monoclonal antihuman ER antibody (Dako) for ER, mouse monoclonal antihuman PR (Dako) for PR, and rabbit monoclonal anti-cytokeratin 19 (Ventana) for HER-2/neu. Qualitative and semi-quantitative measures were recorded. [13] [14] [15] [16] The slides were prepared at our institution and read by one pathologist (H.W.). For the purposes of this study, ER/PR positivity was determined by immunohistochemical analysis of the number of positively stained nuclei ([1 % ?), and membrane staining of HER-2/neu was conducted using scores of 2 and 3 designated as positive. 16 
Statistical Analysis
The categorization of BCS was as follows: luminal A (LA; ER?/PR?/HER-2-), luminal B (LB; ER?/PR?/ HER-2?), HER-2? (ER-/PR-/HER-2?), and triple negative (TN; ER-/PR-/HER-2-). SAS software, version 9.2 (SAS), was used to analyze associations between clinicopathologic characteristics and BCS by Pearson's Chi square or Fisher's exact tests. Analyses of continuous variables by analysis of variance were presented as mean ± 1 SD. Multiple linear regression analysis was used to further explore the association between the clinicopathologic features and BCS, and the Kaplan-Meier analysis was used for outcomes analysis. For this study, a p value of \/=0.05 was considered as statistically significant.
RESULTS
Of the 453 patients who met the inclusion criteria, BCS were classified as followed: 48.5 % (220 of 453) luminal A, 16.1 % (73 of 453) luminal B, 11.0 % (50 of 453) HER-2/neu, and 24.3 % (110 of 453) TN. The median follow-up time for the cohort was 8 years. Of the entire cohort, 111 (24.5 %) had sentinel node biopsy initially, but the vast majority of the cohort went on to have a full axillary lymph node dissection (n = 443, 98 %).
Associations Between BCS and Clinical Parameters
The mean age at diagnosis was found to be significantly different across BCS, with TN and HER-2 presenting at younger ages (TN 47.9 years; HER-2 48.0 years; LA 53.5 years; LB 53 years; p \ 0.001). For method of detection at presentation, patients who had TN disease were much more likely to present with palpable masses, and mammographically detected tumors were most likely to be LA (p = 0.049). The details of this analysis are shown in Table 1 . For associations with race, African American patients were significantly more likely to be of TN or HER-2/neu (p = 0.041).
As expected, there were significant variations in the delivery of systemic therapy based on BCS. The percentages of patients who received adjuvant hormone therapy was significantly higher for LA and LB patients: 64.1 % LA, 71.6 % LB versus 7.8 % triple negative and 5.8 % HER-2 (p \ 0.001) and the patients who received systemic chemotherapy were significantly more often TN-or HER-2-positive: 70.1 % TN, 74.5 % HER-2, 64.1 % LA, and 71.6 % LB (p \ 0.001). The clinical and demographic features as a function of BCS are summarized in Table 1 .
Associations Between BCS and Pathologic Features
There was no association between with BCS and lymph nodes involvement irrespective of whether patients were classified as pN0 versus pN1/pN2 (p = 0.246), node positive versus node negative (p = 0.694), or by absolute number of positive nodes across the four BCS (p = 0.659).
However, there was a statistically significant difference in the pathologic T stage (p \ 0.001); of TN subtype, 44.3 % presented with pT2/pT3 disease compared to 36.2 % of patients with HER-2, 20.2 % of patients with LA, and 26.5 % of patients with LB. There was also a significant association between BCS and histology, with invasive lobular (75 %) and tubular carcinoma (83 %) more likely to be associated with LA, whereas invasive ductal carcinoma (28 %) was most often associated with TN (p \ 0.001). These pathologic findings are listed in Table 2 .
On multiple linear regression modeling, when incorporating age at diagnosis, race, pT stage, method of detection, and pN stage, the associations that remained significant included: pT stage (p = 0.011), race (p \ 0.001), age (p \ 0.001), and method of detection (p \ 0.001), with no statistical significance with pN status (p = 0.846) ( Table 3) . Exploratory analyses of the logistic regression analysis model substituting pN stage with a) absolute number of lymph nodes and b) node? vs. node-disease did not reveal any signficant associations with BCS (data not shown).
BCS and Survival Analysis
Outcomes analyzed included overall survival (OS), distant metastasis-free survival (DMFS), and disease-free survival (DFS). For the OS time in this cohort, the mean survival time was 4.9 ± 0.1 years for TN, 7.0 ± 0.2 years for HER-2, 18.6 ± 0.8 years for LA, and 16.7 ± 0.3 years for LB. As expected, there were significant differences in 10-year outcomes by BCS for OS (p = 0.031), DFS (p = 0.027), and DMFS (p \ 0.001). Details of outcomes are shown in Fig. 1 .
DISCUSSION
Although the number of positive lymph nodes and BCS are both independently well-recognized prognostic indicators, it remains unclear whether there is an association between BCS and nodal involvement. 14, 21 Theoretically, axillary involvement, if associated with BCS, may provide another predictive criterion for therapeutic decisions regarding nodal management. To date, the limited published literature on this topic suggests the relationship between BCS and involvement or extent of lymph node metastasis warrants investigation. In this study, we were not able to demonstrate any significant associations between BCS and lymph node positivity or extent of nodal disease for patients with early-stage disease. However, consistent with the findings of others, BCS was found to be associated with race, age, and outcomes, with a significant distinction in time to distant metastasis, DFS, and OS observed across the four BCS. 8, 22, 23 Furthermore, a statistically significant association between tumor BCS and T stage was also identified.
Although there is a paucity of data on associations between presence or extent of nodal disease across all BCS, conflicting results on the relationship between the TN subtype and nodal disease have been reported. [24] [25] [26] [27] Several publications suggest that basal/TN BCS may predict a lower risk of nodal involvement. 24, 27 Others have suggested a greater extent of nodal disease. 25, 28 This study adds to the existing literature supporting no association between TN subtype and nodal involvement, and furthermore suggests that there is no association with any of the BCS regardless of whether the extent of disease is analyzed as node positive or negative, absolute number of involved lymph nodes, or pN stage. Our findings suggest that nodal involvement at time of clinical presentation is not independently correlated to BCS.
The association between histology and lymph node involvement has been well characterized. For example, patients with invasive lobular carcinoma have a greater likelihood of having multiple positive lymph nodes, and those with tubular carcinoma have significantly less lymph 
Results are reported as n (%) for categorical variables. Percentages may not sum to 100 % as a result of rounding TN triple negative, LA luminal A, LB luminal B, N lymph node, DCIS ductal carcinoma-in situ * Statistically significant at p = 0.05 by either v 2 test or Fisher's exact test df degree of freedom, p pathologic, T tumor, N node node involvement. 19, 29 In the current study, we demonstrated that certain histologic subtypes are more often associated with certain BCS. For example, TN are most often invasive ductal and least likely to be invasive lobular or tubular.
Tumor size, another traditional prognostic feature for outcomes, has been correlated with the probability of axillary lymph node involvement, in addition to survival outcomes and recurrence-free survival rates. [29] [30] [31] For patients with node-negative disease, tumor size remains the most important prognostic factor. 31 We found a significant association between the BCS of breast cancer and T stage, with TN tumors associated with a larger tumor size compared with other subtypes. On the basis of these findings, it is theoretically possible that BCS is primarily associated with characteristics of the primary tumor itself (e.g., tumor size, histology) but is not necessarily indicative of lymph node metastasis. Certainly, tumor size is one prognostic factor that has been described to be associated with inferior outcomes observed in women with TN tumors. 32 The association between the BCS and race has been well described in the literature. 8, 23, 33 African American patients are known to have an increased likelihood of TN breast cancer with inferior OS and DFS. 8, 18 Genome-wide classification studies have suggested that differential expression patterns of molecular subtypes may account for these racial discrepancies in outcomes. Although BCS were initially described and classified by molecular subtypes, immunohistochemical tumor assessment has been found to adequately estimate the molecular analysis with a simpler and more practical method for determining subtypes in the clinical setting. 8, 9 In addition to confirming the association between African American women and TN tumors, our findings of larger tumor size in African American women is also consistent with the existing literature. 18 To validate the parameters recorded within our database, we conducted a confirmatory outcomes analysis by BCS. The existing literature suggests a significant association between BCS and outcomes with the worst DFS, DMFS, and OS for TN subtypes. 8, 11, 34 Our findings are consistent with the existing literature in that we demonstrated a similar association between these outcomes and BCS, with TN having worse overall outcomes. However, it is important to note that in the era in which this cohort was treated, treatment with trastuzumab or other targeted therapy for HER-2 was not available for all the patients, and the outcomes in this BCS have significantly improved in the modern treatment era.
One of the limitations of this study is its retrospective use of clinical data and tumor blocks, which is inevitably associated with the possibility of selection/inclusion bias and information/misclassification bias. We attempted to overcome some of these inherent limitations by conducting a institutional pathologic review, constructing a tissue microarray to allow for prospective categorization of the BCS to minimize intraobserver or interobserver variability and to avoid misclassification bias, and by updating the database parameters and cross-referencing it with our institutional tumor registry data before conducting the analysis to decrease information bias. Reassuringly, our outcomes analysis by BCS is consistent with previously published literature. 6, 7, 35 Given the relative scarcity of literature on association of BCS and clinicopathologic findings at presentation, this study contributes to the existing body of literature on molecular subtypes. 14, 36 Our findings demonstrate that BCS is associated with tumor size, method of detection, histology, race, and age, but not with the presence or extent of axillary nodal disease.
In summary, in this cohort of early-stage breast cancer patients uniformly treated with breast-conserving surgery, surgical assessment of the axilla and adjuvant radiotherapy, significant differences in outcomes across the four BCS were demonstrated, as expected and as previously described. 6, 7 Although a significant association between BCS and nodal involvement was not identified, this study demonstrated a significant association between BCS and primary tumor size, in addition to associations with race, age at diagnosis, method of detection, and histology. This information, together with the finding that tumor BCS was predictive of outcomes, intimates that the mechanism or mechanisms resulting in the inferior survival of TN subtype may not be solely mediated through an advanced N stage at diagnosis. Our hypothesisgenerating findings contribute to the evolution of disease prognosis using BCS and warrant further elucidation. If additionally validated, these findings suggest that the BCS of a tumor may not be a useful prognostic variable for influencing regional management considerations.
